Roivant CEO hints at more deals shap­ing up as key Im­muno­vant da­ta loom

Roivant Sci­ences has more po­ten­tial as­set deals in the works — af­ter set­ting up two Vants around Pfiz­er as­sets in the past two years — and hopes to be talk­ing about them in 2024, CEO Matt Gline told an­a­lysts on a quar­ter­ly earn­ings call on Mon­day morn­ing.

Be­fore that, key da­ta from its fam­i­ly of Vants, in­clud­ing clin­i­cal tri­al read­outs from two an­ti-FcRn as­sets at the pub­licly-trad­ed Im­muno­vant, are on tap. The da­ta could dic­tate the di­rec­tion Roivant takes.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER